IMF Videos Search Content For Care Partner (53) Patient (51) Healthcare Provider (17) Healthcare Professional (16) Series - Any - ASCO/EHA (1) ASH (14) Ask Dr. Durie (40) Black Swan Research Initiative (1) Facebook Live (3) Living Well with Myeloma (1) Patient & Family Webinar (1) Q&A (6) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (12) High-Risk Myeloma (10) High-risk Smoldering Myeloma (12) Late Relapse (4–6 Lines of Therapy) (10) MGUS (23) Newly Diagnosed (Pre-Treatment or First Treatment) (21) Smoldering Myeloma (28) Types of Therapy Immunomodulatory drugs (IMiDs) (8) Immunotherapies (CAR T; BiTE, etc.) (8) Monoclonal antibodies (7) Proteasome inhibitors (5) Stem cell transplant (7) Steroids (4) Supportive Care (20) Year Published 2026 (2) 2025 (4) 2024 (9) 2023 (8) 2022 (10) 2021 (5) 2020 (4) 2019 (9) 2018 (1) 2017 (8) 2016 (4) 2015 (4) Trusted Voices Dr. Brian GM Durie (36) Dr. Joseph Mikhael (7) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (4) Dr. Sigurður Kristinsson (2) Dr. María-Victoria Mateos (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Ultra-Sensitive Assessment of MRD in Peripheral Blood of Multiple Myeloma Patients Using Bloodflow December 26, 2022 ASH Hypercalcemia in Individuals with MGUS: Results from the iStopMM Study December 23, 2022 ASH Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: iStopMM Study December 21, 2022 ASH Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The iStopMM Study December 15, 2022 ASH MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma? December 13, 2022 ASH What does it mean when a myeloma patient is MRD negative? October 6, 2022 Ask Dr. Durie Should patients use mass spectrometry to measure myeloma protein levels? July 7, 2022 Ask Dr. Durie Updates on the Binding Site's ongoing collaboration with the iStopMM study January 27, 2022 ASH Screening for Monoclonal Gammopathy of Undetermined Significance: First Results from the iStopMM Study January 26, 2022 ASH Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on iStopMM Study December 15, 2021 ASH Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial December 13, 2021 ASH How important are the four iStopMM abstracts being presented at ASH for myeloma patients? December 8, 2021 Ask Dr. Durie Load More
